412 related articles for article (PubMed ID: 30530598)
21. Real life experience with ceftolozane/tazobactam therapy for
Khan S; Phe K; Tam VH
J Chemother; 2021 Dec; 33(8):595-597. PubMed ID: 33645440
[No Abstract] [Full Text] [Related]
22. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.
Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620
[TBL] [Abstract][Full Text] [Related]
23. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
MacVane SH; Pandey R; Steed LL; Kreiswirth BN; Chen L
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
[TBL] [Abstract][Full Text] [Related]
24. Ceftolozane-tazobactam for the treatment of multidrug-resistant
Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
Nicolau DP; De Waele J; Kuti JL; Caro L; Larson KB; Yu B; Gadzicki E; Zeng Z; Rhee EG; Rizk ML
Int J Antimicrob Agents; 2021 Apr; 57(4):106299. PubMed ID: 33567333
[TBL] [Abstract][Full Text] [Related]
26. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M
Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
30. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
31. Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.
Monterrubio-Villar J; Rodríguez-Garrido S; Jiménez-Delgado JD
Rev Esp Quimioter; 2018 Aug; 31(4):374-375. PubMed ID: 30014680
[No Abstract] [Full Text] [Related]
32. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
[TBL] [Abstract][Full Text] [Related]
33. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.
Jorgensen SCJ; Trinh TD; Zasowski EJ; Lagnf AM; Simon SP; Bhatia S; Melvin SM; Steed ME; Finch NA; Morrisette T; Estrada SJ; Rosenberg JR; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932379
[TBL] [Abstract][Full Text] [Related]
34. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Munita JM; Aitken SL; Miller WR; Perez F; Rosa R; Shimose LA; Lichtenberger PN; Abbo LM; Jain R; Nigo M; Wanger A; Araos R; Tran TT; Adachi J; Rakita R; Shelburne S; Bonomo RA; Arias CA
Clin Infect Dis; 2017 Jul; 65(1):158-161. PubMed ID: 28329350
[TBL] [Abstract][Full Text] [Related]
35. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
Haidar G; Philips NJ; Shields RK; Snyder D; Cheng S; Potoski BA; Doi Y; Hao B; Press EG; Cooper VS; Clancy CJ; Nguyen MH
Clin Infect Dis; 2017 Jul; 65(1):110-120. PubMed ID: 29017262
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
Gomis-Font MA; Cabot G; López-Argüello S; Zamorano L; Juan C; Moyá B; Oliver A
J Antimicrob Chemother; 2022 Mar; 77(4):957-968. PubMed ID: 35084040
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies.
Chi Y; Xu J; Bai N; Liang B; Cai Y
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):189-201. PubMed ID: 36629486
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
Buonomo AR; Maraolo AE; Scotto R; Foggia M; Zappulo E; Congera P; Parente S; Gentile I
Infection; 2020 Apr; 48(2):303-307. PubMed ID: 31981091
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
[TBL] [Abstract][Full Text] [Related]
40. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
Díaz-Cañestro M; Periañez L; Mulet X; Martin-Pena ML; Fraile-Ribot PA; Ayestarán I; Colomar A; Nuñez B; Maciá M; Novo A; Torres V; Asensio J; López-Causapé C; Delgado O; Pérez JL; Murillas J; Riera M; Oliver A
Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2191-2200. PubMed ID: 30141088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
